French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on September 24, 2026

6 hours ago

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Indeterminate GlobeNewswire

6 hours ago

What CX Leaders Should Understand About Customer Support Outsourcing

Indeterminate GlobeNewswire

6 hours ago

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Indeterminate GlobeNewswire

6 hours ago

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Indeterminate GlobeNewswire

6 hours ago

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Indeterminate GlobeNewswire

6 hours ago

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Indeterminate GlobeNewswire

6 hours ago

PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

Indeterminate GlobeNewswire

6 hours ago

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Indeterminate GlobeNewswire

7 hours ago

Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model

Indeterminate GlobeNewswire

7 hours ago

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Indeterminate GlobeNewswire

7 hours ago

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Indeterminate GlobeNewswire

7 hours ago

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Indeterminate GlobeNewswire

7 hours ago

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Indeterminate GlobeNewswire

7 hours ago

Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000

Indeterminate GlobeNewswire

9 hours ago

Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders

Indeterminate GlobeNewswire

10 hours ago

BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa

Indeterminate GlobeNewswire

10 hours ago

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

Indeterminate GlobeNewswire

10 hours ago

Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment

Indeterminate GlobeNewswire

10 hours ago

フレン・ヘルス、次世代の創傷治療用組換え酵素の製造に、AGCバイオロジクスを選定

Indeterminate GlobeNewswire

10 hours ago

Flen Health, 차세대 상처 치료제용 재조합 효소 생산 위해 AGC Biologics 선정

Indeterminate GlobeNewswire